{
  "id": 1500,
  "text": "This study included patients with stage FIGO IIB-IIIB, or with FIGO stage IB-IIA with biopsy-proven PLN metastases and/or tumour size $\\geq 5 \\ \\mathrm { c m }$ (but with negative PALN).There were no treatment-related serious adverse events, and protocolspecified treatment related adverse events within 90 days of treatment start were reported in $3 1 \\%$ of patients (most common were hematologic: $8 0 \\%$ ).",
  "ChatGPT_query": "Please create a <question> that closely aligns with the provided <text>. Ensure that the <question> is formulated in Chinese and does not explicitly reference the text. You may incorporate specific scenarios or contexts in the <question>, allowing the <text> to serve as a comprehensive and precise answer.\n\n<text>: This study included patients with stage FIGO IIB-IIIB, or with FIGO stage IB-IIA with biopsy-proven PLN metastases and/or tumour size $\\geq 5 \\ \\mathrm { c m }$ (but with negative PALN).There were no treatment-related serious adverse events, and protocolspecified treatment related adverse events within 90 days of treatment start were reported in $3 1 \\%$ of patients (most common were hematologic: \n\n<question>: ",
  "ChatGPT_response_0": "这项研究中包括了病程FIGO IIB-IIIB的患者，或者有经过活组织检查证实的盆腔淋巴结转移和/或瘤体大小≥ 5cm的病程IB-IIA的患者（但淋巴结转移为阴性）。在该研究中，治疗相关的严重不良事件并不存在，而在治疗开始后的90天内报告了协议规定的治疗相关不良事件，占参与者的31%（其中最常见的是血液学方面，占80%）。",
  "query": "这项研究中的患者有哪些病程FIGO IIB-IIIB或有经过活组织检查证实的盆腔淋巴结转移和/或瘤体大小≥ 5cm，但淋巴结转移阴性?",
  "ChatGPT_query_a": "You are HuatuoGPT-II, equipped with in-depth knowledge in medicine. Your task is to directly answer the user's <question> in Chinese. In formulating your response, you must thoughtfully reference the <reference text>, ensuring that your reply does not disclose your reliance on <reference text>. Aim to provide a comprehensive and informative response, incorporating relevant insights from <reference text> to best assist the user. Please be cautious to avoid including any content that might raise ethical concerns.\n\n<question>: 这项研究中的患者有哪些病程FIGO IIB-IIIB或有经过活组织检查证实的盆腔淋巴结转移和/或瘤体大小≥ 5cm，但淋巴结转移阴性?\n\n<reference text>: This study included patients with stage FIGO IIB-IIIB, or with FIGO stage IB-IIA with biopsy-proven PLN metastases and/or tumour size $\\geq 5 \\ \\mathrm { c m }$ (but with negative PALN).There were no treatment-related serious adverse events, and protocolspecified treatment related adverse events within 90 days of treatment start were reported in $3 1 \\%$ of patients (most common were hematologic: $8 0 \\%$ ).\n\n<reply>: ",
  "response": "这项研究中包括了病程FIGO IIB-IIIB的患者，或者有经过活组织检查证实的盆腔淋巴结转移和/或瘤体大小≥ 5cm的病程IB-IIA的患者（但淋巴结转移为阴性）。在该研究中，治疗相关的严重不良事件并不存在，而在治疗开始后的90天内报告了协议规定的治疗相关不良事件，占参与者的31%（其中最常见的是血液学方面，占80%）。"
}